Shield Therapeutics plc
Shield Therapeutics plc is a UK-incorporated (AIM-listed), commercial-stage specialty pharmaceutical company that develops and commercialises ACCRUFeR®/FeRACCRU® (ferric maltol), a differentiated oral iron therapy for iron deficiency with or without anaemia. It sells directly in the U.S. (via a co-commercialisation agreement with Viatris) and out-licenses the product to partners in Europe (Norgine), Canada (Kye Pharmaceuticals), China (ASK Pharma), South Korea (Korea Pharma) and Japan (Medleap Pharma). The Group reached cash-flow positivity in Q4 2025 and is targeting operating profitability in 2026.
No price history · 11 reported years, FY2015–FY2025
No daily prices have been collected for this company.
| Line | FY2015locked | FY2016locked | FY2017locked | FY2018locked | FY2019locked | FY2020locked | FY2021locked | FY2022locked | FY202312/23 | FY202412/24 | FY202512/25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Gross profit | |||||||||||
| Operating profit | |||||||||||
| Net finance cost | |||||||||||
| Profit before tax | |||||||||||
| Tax charge | |||||||||||
| Profit for the year | |||||||||||
| EBITDA | |||||||||||
| Basic EPS | |||||||||||
| Diluted EPS |
GBP millions, negatives in brackets. Per-share lines in pence. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
3 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.